Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
IPO Year: 2021
Exchange: NASDAQ
Website: acurxpharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/29/2021 | $12.00 | Buy | Maxim Group |
Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
ARS - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
DEFA14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
DEF 14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
RW - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
FWP - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a nationally broadcasted business TV show, announces episode 591, airing on the Fox Business Network tonight, Monday, August 26, 2024, at 10:30 PM PT. New to The Street's 591st TV episode line-up features the following five (5) Corporate interviews: 1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) David Luci, President/CEO. 2). "Game Changers" segment interview with Iagon's (CRYPTO: IAG) ($IAG) Dr. Navjit Dhaliwal, CEO. 3). "Game Changers" segment interview with GreenLite Ventures, Inc.'s (OTC:GRNL) ($GRNL) (No Limit Technology Holdings, Inc.) Rafael Groswirt, CEO 4). Sustainable Solu
September 9-11, 2024 STATEN ISLAND, N.Y., Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), today announced it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand. David P. Luci, President & CEO of the Company, will provide an overview of the Company's business during the presentation. If you are an institutional
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a national business TV show, announces episode 590, airing on the FOX Business Network, tonight Monday, August 19, 2024, at 10:30 PM PT. New to The Street's 590th episode line-up features the following five (5) Corporate interviews: 1). Two-Wheel Electric Vehicle (EV) - Zapp Electric Vehicles Group Limited's (NASDAQ:ZAPP) ($ZAPP) Mark Kobal, Head of Investor Relations. 2). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) David Luci, President/CEO. 3). Real Estate - La Rosa Holdings Corp's. (NASDAQ:LRHC) ($LRHC) Joe La Rosa, Founder/CEO, and Deana La Rosa, Ch
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national TV business show, Episode 583, airing on Bloomberg TV as sponsored programming, Saturday, August 10, 2024, at 6:30 PM ET. New to The Street's TV Episode 583 will air the following five (5) riveting business interviews: 1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) David Luci, President/CEO. 2). Water Company – OriginClear, Inc.'s (OTC:OCLN) ($OCLN) Riggs Eckelberry, CEO, Ken Berenger, Executive Vice-President, and Kevin Harrington, Businessman and Panel Member of "Shark Tank" TV show. 3). Sustainable Solutions - The Sustainable Green Team, L
STATEN ISLAND, N.Y., Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024. Highlights of the second quarter ended June 30, 2024, or in some cases shortly thereafter, include: In April 2024, we completed a successful End-of-Phase 2 Clinical Meeting with FDA and confirmed Phase 3 Readiness for ibezapolstat (IBZ) to enter Phase 3 clinical trials for the treatment of C. difficile infection. Agreement with FDA was reached
STATEN ISLAND, N.Y., July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the United States Patent and Trademark Office (USPTO) on July 16, 2024. This patent relates to ibezapolstat and its use to treat C. difficile Infection (CDI) while reducing the recurrence of the infection, as well as improving the health of the gut microbiome. This is the latest in the series of granted patents and pending patent applications that Acrux has filed to protect its proprie
STATEN ISLAND, N.Y., July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2024 financial results on Friday, August 9, 2024 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Friday, August 9, 2024 Time: 8:00 a.m. ET Toll free (U.S
Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treated patients with C. difficile Infection (CDI)Results consistent with those shown in earlier human volunteer studies and Phase 2a studiesPreservation and increased concentrations of beneficial Firmicute (Bacilotta) phylum known to be involved in bile acid homeostasis and short chain fatty acid metabolism was demonstrated Actinobacteria and Bacteroides preservation also confirmed using quantitative analysisSTATEN ISLAND, N.Y., July 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national business TV show airing on Bloomberg TV as sponsored programming tonight, Thursday, June 6, 2024, at 9:30 PM PT. New to The Street's TV episode 576 will air the following four (4) business interviews: 1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) interview with David Luci, President/CEO. 2). Real Estate - La Rosa Holdings Corp's. (NASDAQ:LRHC) ($LRHC) interviews with Joe La Rosa, Founder and CEO, and José Couverte, Team Leader & Talent Acquisition Advisor. 3). "Game Changers" segment interview with Greene Concepts, Inc.'s (OTCMarkets: INKW)
Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial programAgreement also reached with FDA on complete non-clinical and clinical development plan for filing of a New Drug Application for marketing approvalPlanning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)SME (Small and Medium-sized Enterprise) designation has been granted by the EMA (European Medicines Agency), which allows Acurx to benefit from fee incentives and other support from the EMA for EU Marketing AuthorizationAcurx is now preparing to submit requests for guidance to initiate clinical trials in the E
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved
HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $12 price target.
Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial programAgreement also reached with FDA on complete non-clinical and clinical development plan for filing of a New Drug Application for marketing approvalPlanning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)SME (Small and Medium-sized Enterprise) designation has been granted by the EMA (European Medicines Agency), which allows Acurx to benefit from fee incentives and other support from the EMA for EU Marketing AuthorizationAcurx is now preparing to submit requests for guidance to initiate clinical trials in the E
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 12 percent decrease over losses of $(0.25) per share from the same period last year.
Shares of Alcoa Corporation (NYSE:AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter. The company reported quarterly losses of 81 cents per share, according to data from Benzinga Pro. Alcoa still sees full-year alumina production of between 9.8 million and 10 million metric tons and full-year alumina shipments between 12.7 million and 12.9 million metric tons. Alcoa shares jumped 3% to $36.60 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares gained 155.6% to $1.24 in pre-market trading after gaining around 8% on Wednesday. Mic
Gainers Ontrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN) stock moved upwards by 97.41% to $21.0. The company's market cap stands at $1.5 billion. SCWorx (NASDAQ:WORX) stock rose 70.74% to $3.21. The market value of their outstanding shares is at $3.8 million. Enliven Therapeutics (NASDAQ:ELVN) stock increased by 29.19% to $16.33. The company's market cap stands at $675.2 million. The company's, Q4 earnings came out 3 days ago. Vincerx Pharma (NASDAQ:VINC) stock rose 28.31% to $6.3. The market value of their outstanding shares is at $134.6 millio
Gainers Ontrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $14.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN) shares rose 97.46% to $21.01. The company's market cap stands at $1.5 billion. Enveric Biosciences (NASDAQ:ENVB) shares moved upwards by 39.09% to $1.53. The company's market cap stands at $8.2 million. GeneDx Hldgs (NASDAQ:WGS) stock rose 24.22% to $12.0. The market value of their outstanding shares is at $312.6 million. Hoth Therapeutics (NASDAQ:HOTH) shares increased by 22.6% to $1.41. The company's market cap stands at $6.1 million. Enliven Therapeutics (NASDAQ:ELVN) stock rose 17.16% to $14.81. The mark
SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
STATEN ISLAND, N.Y., Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024. Highlights of the second quarter ended June 30, 2024, or in some cases shortly thereafter, include: In April 2024, we completed a successful End-of-Phase 2 Clinical Meeting with FDA and confirmed Phase 3 Readiness for ibezapolstat (IBZ) to enter Phase 3 clinical trials for the treatment of C. difficile infection. Agreement with FDA was reached
STATEN ISLAND, N.Y., July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2024 financial results on Friday, August 9, 2024 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Friday, August 9, 2024 Time: 8:00 a.m. ET Toll free (U.S
STATEN ISLAND, N.Y., May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2024. Highlights of the first quarter ended March 31, 2024, or in some cases shortly thereafter, include: On January 17, 2024, we announced positive comparative microbiology and microbiome data for ibezapolstat in CDI patients from the Phase 2b clinical trial segment. Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile a
STATEN ISLAND, N.Y., April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Wednesday, May 15, 2024 Time:
STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2023. Highlights of the fourth quarter ended December 31, 2023, or in some cases shortly thereafter, include: In October 2023, we ended enrollment in our Phase 2b clinical trial of ibezapolstat, our lead antibiotic candidate, for the treatment of patients with C. difficile infection, or CDI.In November 2023, we reported top-li
STATEN ISLAND, N.Y., March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Monday, March 18, 2024 Time: 8:00 a.m. ET Toll free (U.S.): 877-790-1
STATEN ISLAND, N.Y., Nov. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2023. Highlights of the third quarter ended September 30, 2023, and in some cases shortly thereafter, include: On October 2, 2023, Acurx ended enrollment in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, for the treatment of patients with C. difficile infection, or CDI; On November 2, 2023, Acurx reported top-line data
STATEN ISLAND, N.Y., Aug. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2023. Highlights of the second quarter ended June 30, 2023 include: Acurx continues to enroll patients in its Phase 2b clinical trial, which includes 28 U.S. clinical trial sites, for patients with C. difficile infection (CDI);The Phase 2b clinical trial will compare the efficacy of oral ibezapolstat, the Company's lead antibiotic candidate, to oral vanc
STATEN ISLAND, N.Y., July 24, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2023 financial results on Monday, August 14, 2023, at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Monday, August 14, 2023Time: 8:00 a.m. ETToll free (U.S. and International): 8
STATEN ISLAND, N.Y., May 12, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2023. Highlights of the first quarter ended March 31, 2023 include: Acurx continues to enroll patients in its Phase 2b clinical trial, which now includes 28 U.S. clinical trial sites, for patients with C. difficile infection (CDI);The Phase 2b clinical trial will compare the efficacy of oral ibezapolstat, the Company's lead antibiotic candidate, to oral v